Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Cash & Equivalents (2016 - 2017)

Tenax Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $1.8 million for Q3 2017.

  • For Q3 2017, Cash & Equivalents rose 144.25% year-over-year to $1.8 million; the TTM value through Sep 2017 reached $1.8 million, up 144.25%, while the annual FY2016 figure was $10.0 million, N/A changed from the prior year.
  • Cash & Equivalents for Q3 2017 was $1.8 million at Tenax Therapeutics, down from $2.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $58.3 million in Q2 2014 and bottomed at $722152.0 in Q3 2016.
  • The 5-year median for Cash & Equivalents is $3.3 million (2016), against an average of $8.9 million.
  • The largest annual shift saw Cash & Equivalents crashed 86.41% in 2015 before it surged 173.08% in 2016.
  • A 5-year view of Cash & Equivalents shows it stood at $828811.0 in 2013, then skyrocketed by 6936.65% to $58.3 million in 2014, then plummeted by 93.72% to $3.7 million in 2015, then skyrocketed by 173.08% to $10.0 million in 2016, then crashed by 82.35% to $1.8 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Cash & Equivalents are $1.8 million (Q3 2017), $2.2 million (Q2 2017), and $7.0 million (Q1 2017).